News from BioTrends Research Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

14 Mar, 2013, 08:00 ET U.S. Physicians Report Diabetic Nephropathy as the Renal Condition with the Highest Unmet Need for Treatment

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...


13 Mar, 2013, 11:30 ET BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces the...


06 Mar, 2013, 09:00 ET Growing Uptake of Genzyme's Aubagio at Three Months Post-Launch Is Likely Driven by Perceived Product Convenience Even As Neurologists Search to Identify Appropriate Candidates, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 34...


05 Mar, 2013, 09:30 ET Gastroenterologists Indicate They Are Increasingly Using Biologics to Treat Patients with Crohn's Disease in Remission than They Were One Year Ago, According to a Recent BioTrends Report

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, although...


07 Feb, 2013, 09:00 ET EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized...


05 Feb, 2013, 09:00 ET EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the...


16 Jan, 2013, 08:00 ET Even with Aubagio's Recent Launch, the Impact of Gilenya and Tysabri Label Revisions Continue to Dominate Changes in the U.S. Multiple Sclerosis Market, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...


14 Jan, 2013, 08:00 ET U.S. Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs; Physicians Find High Interest in HIF Inhibitors SFP, Zerenex and CTAP101

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds declining...


09 Jan, 2013, 08:00 ET Oral Formulation Drives Early Trial of Genzyme's Aubagio, Although Safety Concerns are Identified as Obstacles at One Month Post-Launch, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 16...


08 Jan, 2013, 08:00 ET Although Usage Remains Low Six Months Post-Launch, U.S. Nephrologists Continue to Report High Anticipated Future Use of Omontys

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings...


07 Jan, 2013, 08:00 ET Recent Eylea Growth Appears to be Coming from Expanded Uptake Among Prescribers Rather than from Initial Trial Among Late Adopters, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, after...